Literature DB >> 7573005

Increasing mortality from thrombotic thrombocytopenic purpura in the United States--analysis of national mortality data, 1968-1991.

T J Török1, R C Holman, T L Chorba.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disease and the epidemiologic features have been incompletely characterized. Because of the historically high case-fatality rate for TTP, we analyzed U.S. multiple cause-of-death mortality data with TTP listed on the death record for the period 1968-1991, in order to estimate the incidence of TTP, to characterize demographic features of the decedents, and to determine if trends in mortality correlate with findings from clinical studies showing improved survival in recent years. There were 4,523 TTP-associated deaths during the 24-year study period. The annual age-adjusted mortality rate decreased initially and reached its lowest point at 0.4 per 1,000,000 residents for the years 1970 through 1973, and then increased steadily to 1.1 during the last 4 years of the study period, 1988 through 1991. We estimate the current incidence of TTP to be approximately 3.7 cases per 1,000,000 residents. Deaths were rare below the age of 20 years, but the age-specific mortality rate for those 20 years and older increased steadily with increasing age. Regardless of age, females were affected more often than males, and the overall female-to-male age-adjusted rate ratio was 1.9 (95% confidence interval (CI), 1.8 to 2.0). The greatest age-specific difference was between females and males in their twenties (rate ratio 3.2; 95% CI, 2.6 to 3.9). The mortality rate for blacks, and especially black females, was higher than the mortality rate for whites (black-to-white age-adjusted rate ratio 3.4; 95% CI, 3.2 to 3.6; black female-to-white female age-adjusted rate ratio 3.6; 95% CI, 3.3 to 3.9), although the majority of deaths were among whites (71.5%). Infection with the human immunodeficiency virus (HIV) or an HIV-related diagnosis was reported in 61 (1.3%) decedents overall and in 51 (4.4%) decedents from 1988 through 1991. The TTP mortality rate has increased over time despite reports of significant improvement in survival associated with clinical use of plasma infusion and plasma exchange. This trend in mortality suggests that the incidence of TTP is increasing. Blacks, and black females in particular, are affected at a disproportionately high rate. The increased incidence of HIV infection and related disease may have contributed to some of the increase in TTP mortality in recent years, but it does not explain the majority of the increase, which began before the onset of the HIV epidemic.

Entities:  

Mesh:

Year:  1995        PMID: 7573005     DOI: 10.1002/ajh.2830500203

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  39 in total

Review 1.  Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.

Authors:  P A McCullough; K R Marks
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

2.  Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.

Authors:  F L Paradiso-Hardy; C M Angelo; K L Lanctôt; E A Cohen
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

3.  Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature.

Authors:  Arife Ulas; Kamile Silay; Sema Akinci; Muhammed Bulent Akinci; Mehmet Ali Sendur; Didem Sener Dede; Yunus Halil Polat; Bulent Yalcin
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

Review 4.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

5.  Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Authors:  Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 6.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

7.  Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Authors:  Mehran Karimi; Ameneh Sabzi; Flora Peyvandi; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

8.  Thrombotic thrombocytopenic purpura associated with myelodysplastic syndrome.

Authors:  Nana Sasaki; Junya Kuroda; Eri Kawata; Teruaki Akaogi; Miki Kiyota; Yutaka Kobayashi; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2008-10-23       Impact factor: 2.490

9.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

Review 10.  Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).

Authors:  Anaadriana Zakarija; Hau C Kwaan; Joel L Moake; Nicholas Bandarenko; Dilip K Pandey; June M McKoy; Paul R Yarnold; Dennis W Raisch; Jeffrey L Winters; Thomas J Raife; John F Cursio; Thanh Ha Luu; Elizabeth A Richey; Matthew J Fisher; Thomas L Ortel; Martin S Tallman; X Long Zheng; Masanori Matsumoto; Yoshihiro Fujimura; Charles L Bennett
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.